고혈압 환자에서 당뇨병 유무에 따른 원발성 알도스테론증의 유병률 비교 = Comparing the Prevalence of Primary Aldosteronism in Hypertensive Diabetic and Non-diabetic Patients

다국어 초록 (Multilingual Abstract)

Background: Primary aldosteronism is the most common cause of secondary hypertension in humans. Its prevalence is estimated to be 10-15% among hypertensive patients. It is also associated with insulin resistance and diabetes mellitus. The aim of our study was to compare the prevalence of primary aldosteronism in hypertensive patients with presence of diabetes mellitus.
Methods: We reviewed retrospectively the clinical records of 104 hypertensive patients for whom we also measured plasma renin activity (PRA) and plasma aldosterone concentrations (PAC).
Results: Among 104 hypertensive patients, 44 had diabetes and 60 did not. There were no significant differences in clinical characteristics between non-diabetic and diabetic patients except for age and the number of antihypertensive agents. Patients with target organ damage were more common among diabetic patients. There was no correlation between PAC and the number of target organs damaged. In addition, Four patients from the non-diabetic and two from the diabetic group had a ratio over 30 for PRA/PAC and a PAC of over 15 ng/dL. Two non-diabetic patients and one diabetic patient were found, on abdomen CT, to have an adrenal adenoma. The rest of the patients refused further tests.
Conclusion: The prevalence of primary aldosteronism in diabetic patients does not differ significantly from that in non-diabetic patients. Therefore, the present routine screening test for primary aldosteronism in hypertensive diabetic patients is not recommended.

다국어 초록 (Multilingual Abstract)

Background: Primary aldosteronism is the most common cause of secondary hypertension in humans. Its prevalence is estimated to be 10-15% among hypertensive patients. It is also associated with insulin resistance and diabetes mellitus. The aim of our study was to compare the prevalence of primary aldosteronism in hypertensive patients with presence of diabetes mellitus.
Methods: We reviewed retrospectively the clinical records of 104 hypertensive patients for whom we also measured plasma renin activity (PRA) and plasma aldosterone concentrations (PAC).
Results: Among 104 hypertensive patients, 44 had diabetes and 60 did not. There were no significant differences in clinical characteristics between non-diabetic and diabetic patients except for age and the number of antihypertensive agents. Patients with target organ damage were more common among diabetic patients. There was no correlation between PAC and the number of target organs damaged. In addition, Four patients from the non-diabetic and two from the diabetic group had a ratio over 30 for PRA/PAC and a PAC of over 15 ng/dL. Two non-diabetic patients and one diabetic patient were found, on abdomen CT, to have an adrenal adenoma. The rest of the patients refused further tests.
Conclusion: The prevalence of primary aldosteronism in diabetic patients does not differ significantly from that in non-diabetic patients. Therefore, the present routine screening test for primary aldosteronism in hypertensive diabetic patients is not recommended.

참고문헌 (Reference)

1 박주리, "원발성 알도스테론증과 본태성 고혈압에서의 표적장기 손상 빈도 비교" 대한내분비학회 22 (22): 11-18, 2007

2 Perkins JM, "The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control" 15 : 147-152, 2008

3 Giacchetti G, "The renin-angiotensin-aldosterone system, glucose metabolism and diabetes" 16 : 120-126, 2005

4 Strain WD, "The renin-angiotensin- aldosterone system and the eye in diabetes" 3 : 246-, 2002

5 Jefic D, "The prevalence of primary aldosteronism in diabetic patients" 8 : 253-256, 2006

6 Price DA, "The paradox of the low-renin state in diabetic nephropathy" 10 : 2382-2391, 1999

7 Gallay BJ, "Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio" 37 : 699-705, 2001

8 Schwartz GL, "Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin acitivity" 2005 51 : 386-394, 2005

9 Rossi GP, "Primary aldosteronism: an update on screening, diagnosis and treatment" 26 : 613-621, 2008

10 Umpierrez GE, "Primary aldosteronism in diabetic subjects with resistant hypertension" 30 : 1699-1703, 2007

11 Nishikawa T, "Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication?" 54 : 487-495, 2007

12 Sung YA, "Mechanism of angiotensin 2 - stimulated aldosterone secretion in adrenal glomerulosa cells of diabetic rats; normal phospholipase activity and intracellular calcium mobilization" 12 : 230-244, 1997

13 Shigematsu Y, "Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism" 29 : 723-727, 1997

14 Campión J, "Inhibition by aldosterone of insulin receptor mRNA levels and insulin binding in U-937 human promonocytic cells" 70 : 211-218, 1999

15 Fredersdorf S, "Increased aldosterone levels in a model of type 2 diabetes mellitus" 117 : 15-20, 2009

16 Stowasser M, "High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients" 21 : 2149-2157, 2003

17 Mulatero P, "Drug effects on aldosterone/ plasma renin activity ratio in primary aldosteronism" 40 : 897-902, 2002

18 Seiler L, "Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication" 150 : 329-337, 2004

19 Sowers JR, "Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update" 26 : 869-879, 1995

20 Mantero F, "Detecting and treating primary aldosteronism: primary aldosteronism" 115 : 171-174, 2007

21 McFarlane SI, "Cardiovascular endocrinology l: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease" 88 : 516-523, 2003

22 Calhoun DA, "Aldosteronism and hypertension" 1 : 1039-1045, 2006

23 Fallo F, "Adiponectin and insulin sensitivity in primary aldosteronism" 20 : 855-861, 2007